Claus K HÃ¸gdall

List of Publications by Year
in descending order

89 papers	2,585 citations	218381 26 h-index	233125 45 g-index
90 all docs	90 docs citations	90 times ranked	5401 citing authors

#	Article	IF	Citations
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
2	MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer â€" A multicenter prospective comparative study. Gynecologic Oncology, 2013, 128, 300-308.	0.6	183
3	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
4	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. Gynecologic Oncology, 2007, 104, 508-515.	0.6	122
5	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
6	Annexin A2 and cancer: A systematic review. International Journal of Oncology, 2018, 52, 5-18.	1.4	82
7	A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer â€" An international multicenter study in women with an ovarian mass. Gynecologic Oncology, 2015, 138, 640-646.	0.6	78
8	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€"ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
9	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
10	HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2285-2295.	1.1	65
11	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
12	Danish Gynecological Cancer Database. Clinical Epidemiology, 2016, Volume 8, 485-490.	1.5	51
13	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
14	Comorbidity is an independent prognostic factor for the survival of ovarian cancer: A Danish register-based cohort study from a clinical database. Gynecologic Oncology, 2013, 129, 97-102.	0.6	46
15	Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 273-279.	1.3	37
16	Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS ONE, 2018, 13, e0207319.	1.1	35
17	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
18	Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study. Journal of Gynecologic Oncology, 2019, 30, e84.	1.0	35

#	Article	IF	Citations
19	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
20	Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecologic Oncology, 2016, 142, 50-53.	0.6	33
21	Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer â€“ A population-based study. European Journal of Cancer, 2020, 128, 47-56.	1.3	31
22	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecologic Oncology, 2015, 136, 205-211.	0.6	30
23	Current status on micro<scp>RNA</scp>s as biomarkers for ovarian cancer. Apmis, 2016, 124, 337-355.	0.9	30
24	Risk of recurrence, prognosis, and followâ€up for Danish women with cervical cancer in 2005â€2013: A national cohort study. Cancer, 2018, 124, 943-951.	2.0	29
25	PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget, 2015, 6, 32266-32278.	0.8	28
26	Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities â€” A systematic review. Gynecologic Oncology, 2015, 136, 571-581.	0.6	27
27	Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. OncoImmunology, 2018, 7, e1412029.	2.1	27
28	Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? â€“ A cohort study among Danish women diagnosed 2005â€“2010. Cancer Epidemiology, 2015, 39, 353-359.	0.8	26
29	Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review). Molecular and Clinical Oncology, 2019, 10, 323-330.	0.4	26
30	Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS ONE, 2019, 14, e0225249.	1.1	24
31	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
32	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
33	Survival of ovarian cancer patients in Denmark: Results from the Danish gynaecological cancer group (DGCG) database, 1995â€“2012. Acta OncolÃ³gica, 2016, 55, 36-43.	0.8	22
34	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468.	0.8	20
35	Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIBâ€IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 34-43.	1.3	20
36	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19

#	Article	IF	Citations
37	A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIICâ€“IV ovarian cancerâ€”a part of the Danish prospective pelvic mass study. Tumor Biology, 2016, 37, 12619-12626.	0.8	19
38	Oncomineâ„¢ Comprehensive Assay v3 vs. Oncomineâ„¢ Comprehensive Assay Plus. Cancers, 2021, 13, 5230.	1.7	19
39	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
40	Does stage of cancer, comorbidity or lifestyle factors explain educational differences in survival after endometrial cancer? A cohort study among Danish women diagnosed 2005â€“2009. Acta OncolÃ³gica, 2016, 55, 680-685.	0.8	17
41	International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. International Journal of Gynecological Cancer, 2018, 28, 915-924.	1.2	17
42	Next Generation Sequencing Technology in the Clinic and Its Challenges. Cancers, 2021, 13, 1751.	1.7	17
43	The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Research, 2002, 22, 1765-8.	0.5	17
44	A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients. Gynecologic Oncology, 2016, 141, 471-478.	0.6	15
45	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
46	The prevalence of EBV and CMV DNA in epithelial ovarian cancer. Infectious Agents and Cancer, 2019, 14, 7.	1.2	15
47	Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. Apmis, 2002, 110, 630-638.	0.9	14
48	Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemporary Clinical Trials Communications, 2017, 8, 167-174.	0.5	14
49	Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?. International Journal of Gynecological Cancer, 2017, 27, 1123-1133.	1.2	12
50	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
51	Survival outcomes in patients with cervical cancer after inclusion of PET/CT in staging procedures. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1833-1839.	3.3	11
52	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS ONE, 2017, 12, e0174300.	1.1	11
53	Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study. Gynecologic Oncology, 2019, 155, 112-118.	0.6	11
54	Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. Scientific Reports, 2021, 11, 5438.	1.6	11

#	Article	IF	Citations
55	Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study. Journal of Gynecologic Oncology, 2020, 31, e22.	1.0	11
56	HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. Apmis, 2016, 124, 1038-1045.	0.9	10
57	Examining validity evidence for a simulation-based assessment tool for basic robotic surgical skills. Journal of Robotic Surgery, 2019, 13, 99-106.	1.0	10
58	Association of CD31 and p53 With Survival of Ovarian Cancer Patients. Anticancer Research, 2019, 39, 567-576.	0.5	10
59	Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. Cancers, 2021, 13, 5242.	1.7	10
60	Valid and complete data on endometrial cancer in the Danish Gynaecological Cancer Database. Danish Medical Journal, 2014, 61, A4864.	0.5	10
61	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Research, 2019, 39, 2475-2482.	0.5	9
62	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
63	Postpartum hematoma and vaginal packing with a blood pressure cuff. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 887-889.	1.3	7
64	Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer â€“ A nationwide study. Gynecologic Oncology, 2020, 156, 124-130.	0.6	7
65	Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. Reproductive Sciences, 2021, 28, 757-765.	1.1	7
66	DNA Methylation in Ovarian Tumorsâ€”a Comparison Between Fresh Tissue and FFPE Samples. Reproductive Sciences, 2021, 28, 3212-3218.	1.1	7
67	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. Clinica Chimica Acta, 2021, 522, 152-157.	0.5	7
68	Realâ€life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<scp>RESPONSE</scp> trial). Cancer, 2022, 128, 3080-3089.	2.0	7
69	Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients â€“ a comparative cohort study. Acta OncolÃ³gica, 2018, 57, 1100-1108.	0.8	6
70	The effect of introducing pelvic lymphadenectomy on survival and recurrence rates in Danish endometrial cancer patients at high risk: a Danish Gynecological Cancer Group study. International Journal of Gynecological Cancer, 2019, 29, 68-76.	1.2	6
71	Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1034-1042.	1.2	6
72	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.0	6

#	Article	IF	Citations
73	Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population. International Journal of Gynecological Cancer, 2021, 31, 1116-1124.	1.2	6
74	Location of recurrences in high-risk stage Iendometrial cancer patients not given postoperative radiotherapy: A Danish gynecological cancer group study. International Journal of Gynecological Cancer, 2019, 29, 497-504.	1.2	5
75	Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. Oncotarget, 2017, 8, 108213-108222.	0.8	5
76	Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 334-343.	1.3	5
77	Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 507-514.	1.4	4
78	Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. PLoS ONE, 2021, 16, e0255142.	1.1	4
79	The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer. Anticancer Research, 2016, 36, 5373-5380.	0.5	4
80	Risk factors for early death among ovarian cancer patients: a nationwide cohort study. Journal of Gynecologic Oncology, 2020, 31, e30.	1.0	4
81	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
82	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancerâ€"A Multicenter Analysis. Cancers, 2022, 14, 1954.	1.7	3
83	First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion Diagnostic. Journal of Nuclear Medicine, 2022, 63, 1871-1879.	2.8	3
84	The 10-year results after national introduction of pelvic lymph node staging in Danish intermediate-risk endometrial cancer patients not given postoperative radiotherapy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 263, 239-246.	0.5	2
85	The prospect of discovering new biomarkers for ovarian cancer based on current knowledge ofï¿½susceptibility loci and genetic variation (Review). International Journal of Molecular Medicine, 2019, 44, 1599-1608.	1.8	2
86	Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma. Gynecologic Oncology, 2022, 164, 543-549.	0.6	2
87	Organoids and epithelial ovarian cancer â€' a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29.	0.4	2
88	Preoperative predictors of inguinal lymph node metastases in vulvar cancer â€" A nationwide study. Gynecologic Oncology, 2022, 165, 420-427.	0.6	2
89	Postoperative mobilisation as an indicator for the quality of surgical nursing care. British Journal of Nursing, 2021, 30, S4-S15.	0.3	1